Europe's health systems need to adapt to allow patients and citizens to benefit from organised pathways for early diagnosis of lung cancer, say the European Society of Radiology (ESR) and the European Respiratory Society (ERS).
In a statement paper, the ESR and ERS say now is the time to convince policymakers across the European Union (EU) that this is “an urgent societal and political need”.
The paper - an update of the first joint ESR/ERS white paper on lung cancer screening (LCS) published in 2015 - calls for both top-down and bottom-up advocacy to raise awareness of the need to introduce screening at a national level and effectively progress its implementation.
It urges the formulation of minimum standards and analysis of benefits and harms for implementation of nationwide, population-based low-dose CT (LDCT) LCS in European countries. It recommends regular surveillance of the latest evidence on LDCT LCS by a core ERS-ESR team, with updates as needed.
The organisations also say, if feasible, an umbrella European registry/analysis unit should be established and linked to national registries for quality assurance and further research.